Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment


Autoři: Yu-Shan Chang aff001;  Ying-Tin Chen aff002;  Tso-Ting Lai aff003;  Hung-Chieh Chou aff004;  Chien-Yi Chen aff004;  Wu-Shiun Hsieh aff004;  Chung-May Yang aff003;  Po-Ting Yeh aff003;  Po-Nien Tsao aff004
Působiště autorů: Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan aff001;  Department of Pediatrics, China Medical University Children's Hospital, Taichung, Taiwan aff002;  Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan aff003;  Department of Pediatrics, National Taiwan University Children’s Hospital, Taipei, Taiwan aff004;  The Research Center for Developmental Biology and Regenerative Medicine, National Taiwan University, Taipei, Taiwan aff005
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0223972

Souhrn

This single-centered, retrospective cohort study investigated the timing of involution of retinopathy of prematurity (ROP) and retinal vascularization to zone III after intravitreal bevacizumab (IVB) treatment and its possible impacts on postnatal growth and neurodevelopment. Premature infants with birth weight ≤1500 g, born between 2008 to 2014 and diagnosed with ROP were enrolled. All patients with type 1 ROP underwent IVB as 1st line treatment and were recruited as the study group; those with any stage of ROP except type 1 ROP without treatment served as controls. Neurodevelopmental outcomes were assessed using the Bayley Score of Infant Development (BSID) editions II or III. The study group included 35 eyes from 18 patients; the control group included 86 patients. Twenty-three eyes (65.7%) exhibited ROP regression after a single dose of IVB. The majority of plus sign and extraretinal neovascularization regressed within two weeks. The length of time for retinal vascularization to reach zone III was significantly longer in the treatment group compared with the control (mean post-menstruation age 54.5 vs. 47.0 weeks, p<0.001). Long-term follow-up showed no significant differences in body weight and neurodevelopment between the study and control groups up to the 2-year corrected age.

Klíčová slova:

Birth weight – Body weight – Eyes – Infants – Lasers – Neonates – Retina – Retinopathy of prematurity


Zdroje

1. Hussain N, Clive J, Bhandari V. Current incidence of retinopathy of prematurity, 1989–1997. Pediatrics. 1999;104(3):e26. Epub 1999/09/02. doi: 10.1542/peds.104.3.e26 10469809.

2. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1991;98(11):1628–40. Epub 1991/11/01. doi: 10.1016/s0161-6420(91)32074-8 1800923.

3. Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics. 2005;115(4):990–6. Epub 2005/04/05. doi: 10.1542/peds.2004-1309 15805375.

4. Haines L, Fielder AR, Baker H, Wilkinson AR. UK population based study of severe retinopathy of prematurity: screening, treatment, and outcome. Archives of disease in childhood Fetal and neonatal edition. 2005;90(3):F240–4. Epub 2005/04/23. doi: 10.1136/adc.2004.057570 15846016; PubMed Central PMCID: PMC1721880.

5. Todd DA, Wright A, Smith J. Severe retinopathy of prematurity in infants <30 weeks' gestation in New South Wales and the Australian Capital Territory from 1992 to 2002. Archives of disease in childhood Fetal and neonatal edition. 2007;92(4):F251–4. Epub 2007/01/26. doi: 10.1136/adc.2006.096479 17251225; PubMed Central PMCID: PMC2675420.

6. Good WV. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Transactions of the American Ophthalmological Society. 2004;102:233–48; discussion 48–50. Epub 2005/03/08. 15747762; PubMed Central PMCID: PMC1280104.

7. Fierson WM, American Academy of Pediatrics Section on O, American Academy of O, American Association for Pediatric O, Strabismus, American Association of Certified O. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131(1):189–95. Epub 2013/01/02. doi: 10.1542/peds.2012-2996 23277315.

8. Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2007;245(11):1727–30. Epub 2007/08/11. doi: 10.1007/s00417-007-0661-y 17690897.

9. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. The New England journal of medicine. 2011;364(7):603–15. Epub 2011/02/18. doi: 10.1056/NEJMoa1007374 21323540; PubMed Central PMCID: PMC3119530.

10. Chen YH, Chen SN, Lien RI, Shih CP, Chao AN, Chen KJ, et al. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye (London, England). 2014;28(9):1080–6; quiz 7. Epub 2014/08/12. doi: 10.1038/eye.2014.172 25104736; PubMed Central PMCID: PMC4166639.

11. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Archives of ophthalmology (Chicago, Ill: 1960). 2003;121(12):1684–94. Epub 2003/12/10. doi: 10.1001/archopht.121.12.1684 14662586.

12. Chan-Kai BT, Lauer AK. Transconjunctival, sutureless 25-gauge lens sparing vitrectomy for stage 4 retinopathy of prematurity-related retinal detachments. Retina (Philadelphia, Pa). 2009;29(6):854–9. Epub 2009/06/12. doi: 10.1097/IAE.0b013e3181a3b7b1 19516123

13. Isaac M, Tehrani N, Mireskandari K. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up. Eye (London, England). 2016;30(3):333–41. Epub 2016/02/13. doi: 10.1038/eye.2015.289 26869159; PubMed Central PMCID: PMC4791711.

14. Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Investigative ophthalmology & visual science. 2010;51(3):1606–8. Epub 2009/10/31. doi: 10.1167/iovs.09-4140 19875666.

15. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5):855–9. Epub 2007/05/01. doi: 10.1016/j.ophtha.2007.01.017 17467524.

16. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, et al. VEGF is required for growth and survival in neonatal mice. Development (Cambridge, England). 1999;126(6):1149–59. Epub 1999/02/18. 10021335.

17. Teng H, Zhang ZG, Wang L, Zhang RL, Zhang L, Morris D, et al. Coupling of angiogenesis and neurogenesis in cultured endothelial cells and neural progenitor cells after stroke. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2008;28(4):764–71. Epub 2007/11/01. doi: 10.1038/sj.jcbfm.9600573 17971789; PubMed Central PMCID: PMC2744583.

18. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochemical pharmacology. 2001;61(3):253–70. Epub 2001/02/15. doi: 10.1016/s0006-2952(00)00529-3 11172729.

19. Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics. 2016;137(4). Epub 2016/06/01. doi: 10.1542/peds.2015-3218 27244705.

20. Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC, et al. Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment. PloS one. 2016;11(1):e0148019. Epub 2016/01/28. doi: 10.1371/journal.pone.0148019 26815000; PubMed Central PMCID: PMC4729687.

21. Araz-Ersan B, Kir N, Tuncer S, Aydinoglu-Candan O, Yildiz-Inec D, Akdogan B, et al. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. Current eye research. 2015;40(6):585–91. Epub 2014/07/16. doi: 10.3109/02713683.2014.941070 25025864.

22. Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, Kon-Jara VA, Garcia-Aguirre G, Guerrero-Naranjo JL, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina (Philadelphia, Pa). 2013;33(2):329–38. Epub 2012/10/27. doi: 10.1097/IAE.0b013e318275394a 23099498.

23. Kennedy KA, Mintz-Hittner HA. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. Journal of AAPOS: the official publication of the American Association for Pediatric Ophthalmology and Strabismus / American Association for Pediatric Ophthalmology and Strabismus. 2018;22(1):61–5.e1. Epub 2017/12/11. doi: 10.1016/j.jaapos.2017.10.006 29223789; PubMed Central PMCID: PMC5826862.

24. Hong YR, Kim YH, Kim SY, Nam GY, Cheon HJ, Lee SJ. PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION. Retina (Philadelphia, Pa). 2015;35(9):1772–7. Epub 2015/04/02. doi: 10.1097/IAE.0000000000000535 25829347.

25. Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Investigative ophthalmology & visual science. 2015;56(2):956–61. Epub 2015/01/24. doi: 10.1167/iovs.14-15842 25613938.

26. Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA ophthalmology. 2015;133(4):391–7. Epub 2015/01/09. doi: 10.1001/jamaophthalmol.2014.5373 25569026.

27. Huang CY, Lien R, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2018;256(3):479–87. Epub 2018/01/01. doi: 10.1007/s00417-017-3878-4 29290015.

28. Wu WC, Shih CP, Lien R, Wang NK, Chen YP, Chao AN, et al. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY. Retina (Philadelphia, Pa). 2017;37(4):694–701. Epub 2016/07/29. doi: 10.1097/IAE.0000000000001209 27467377.

29. Hellgren G, Lofqvist C, Hard AL, Hansen-Pupp I, Gram M, Ley D, et al. Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity. Pediatric research. 2016;79(1–1):70–5. Epub 2015/09/16. doi: 10.1038/pr.2015.181 26372519

30. Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, et al. Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmol. 2017;135(6):654–6. Epub 2017/04/28. doi: 10.1001/jamaophthalmol.2017.1055 28448664; PubMed Central PMCID: PMC5521814.

31. Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, et al. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments. Ophthalmology. 2018. Epub 2018/06/12. doi: 10.1016/j.ophtha.2018.05.001 29887334.

32. Castellanos MA, Schwartz S, Garcia-Aguirre G, Quiroz-Mercado H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. The British journal of ophthalmology. 2013;97(7):816–9. Epub 2012/12/12. doi: 10.1136/bjophthalmol-2012-302276 23221964.


Článek vyšel v časopise

PLOS One


2019 Číslo 10